Skip to main content

Advertisement

Table 1 All of the long non coding RNAs involved in tumor progressions among Iranian patients

From: Long non-coding RNAs as the critical factors during tumor progressions among Iranian population: an overview

Study (et al.)YearTypeGenePopulationResults
Shahryari [37]2014ESCCSOX2OT36 N/TaOver expression
Rezaei [45]2016Esophageal, ovarian, cervical, breast, sarcoma, colon, and melanomaLINC-ROR27 N/TEsophageal, ovarian, and cervical cancers had over expressions while breast, sarcoma, colon, and melanoma had under expressions
Sahebi [49]2016ESCCLINC-ROR30 N/TOver expression
Rahimnia [51]2018ESCClnc-POU3F332 patients
32 controls
Over expression
Razavi [56]2019ESCClnc-PCAT-175 N/TOver expression
Bayat [58]2018ProstatePrcat17.3, Prcat38, Cat2184.430 N/TPrcat17.3 and Prcat38 over expressions and Cat2184.4 under expression
Taheri [60]2017ProstateHOTAIR128 patients
250 controls
Polymorphism was correlated with tumor progression
Taheri [64]2017ProstateANRIL125 patients
220 controls
Polymorphism was correlated with tumor progression
Sattarifard [66]2017ProstatePRNCR1178 patients
180 BPHb
Polymorphism was correlated with tumor progression
Yazarlou [83]2018BladderLINC00355, UCA1-203, MALAT1, and UCA1-20159 patients
24 controls
LINC00355, UCA1-203, and MALAT1 over expressions. UCA1-201 under expression
Farhangian [88]2018GastricSOX2OT33 N/TUnder expression
Hajjari [90]2013GastricHOTAIR31 N/TOver expression
Emadi-Andani [91]2014GastricHOTAIR60 N/TOver expression
Baratieh [97]2017GastricPlncRNA-1 and TUG170 N/TOver expression
Aminian [103]2019GastricGAS5130 patients
230 controls
Polymorphism was correlated with tumor progression
Kangarlouei [106]2019GastricANRIL and ANRASSF139 N/TOver expression
Iranpour [111]2016BreastSOX2OT, PTPRG-AS1, ANRASSF1, and ANRIL38 N/TOver expression
Hassanzarei [114]2017BreastHOTAIR220 patients
231 controls
Polymorphism was correlated with tumor progression
Hassanzarei [118]2017BreastH19230 patients
240 controls
Polymorphism was correlated with tumor progression
Safari [119]2019BreastH19111 patients
130 controls
Polymorphism was correlated with tumor progression
Abdollahzadeh [120]2019BreastH19150 patients
100 controls
Polymorphism was correlated with tumor progression
Arshi [130]2018BreastMALAT1, SRA, NEAT1, and GAS523 patients
15 controls
MALAT1, SRA, and NEAT1 over expressions. GAS5 under expression
Soleimanpour [135]2018BreastPRNCR130 N/TOver expression
Ravanbakhsh [138]2019BreastlncUSMycN52 N/TOver expression
Rezanejad Bardaji [140]2018ColorectalZEB1-AS132 N/TOver expression
Kazemzadeh [143]2017ColorectalLOC10028722530 N/TUnder expression
Kazemzadeh [142]2016ColorectalLOC10028722539 N/TUnder expression
Rezanejad bardaji [144]2018ColorectalVIM-AS135 N/TOver expression
Hashemi [146]2016ALLlnc-LAMC2-1:1110 patients
120 controls
Polymorphism was correlated with tumor progression
Esfandi [150]2018LungOIP5-AS32 N/TUnder expression
  1. aTumor tissues and normal margins
  2. bBenign prostatic hyperplasia